Shorted
Immuron logo
IMC
Pharmaceuticals, Biotechnology & Life Sciences

Immuron

Short interest
0.14%
+0.12 pp 30d
as of 21 July 2025
Reported shorts
380K
Shares on issue
268.220M

Immuron (IMC) financials

Results, ratios and statements

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue
$7.7M (source: ASX (Markit))vs $7.3M (FY25)
ASX (Markit), as at 14 Oct 2026
NPAT
−$3.7M (source: ASX (Markit))vs −$5.2M (FY25)
ASX (Markit), as at 14 Oct 2026
EPS (diluted)
−$0.013 (source: Derived: trailing 12 months at year end)vs −$0.023 (FY25)
Derived: trailing 12 months at year end, as at 14 Oct 2026
Rev YoY
+5.9%FY
EPS YoY
n/aTTM
  • ASX (Markit)
  • Derived: trailing 12 months at year end

Summary of Annual Report, 24 Sep 2026

Immuron reported record revenue of A$7.7 million for FY26, up 6% on FY25, but posted a net loss of A$3.7 million, an improvement from the prior year's loss of A$5.2 million. No dividend was declared. The company is advancing its clinical pipeline through partnerships and launching PROIBS® in the US.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); balance sheet at 31 Dec 2025, 6 months before; prices to 14 Oct 2026

Gross margin
64.5%
Operating margin
−48.3%
Net margin
−47.7%
FCF margin
−42.3%
ROE
n/a
ROA
n/a
FCF conversion
n/a
Net debt (excl. leases)
n/a
Net debt / EBITDA
n/a
Current ratio
8.0×
Interest cover
−253.1×
Cash dividends paid / net profit
n/a
Market cap
$12.4M
P/E
n/a
P/B
0.9×

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

IMC income, newest period first, figures in AUD
Line itemFY26FY25FY24FY23
Revenue$7.7M (source: ASX (Markit))$7.3M$4.9M$1.8M
Gross profit$5.0M (source: Derived: trailing 12 months at year end)$4.8M$3.3M$1.3M
Operating income−$3.7M (source: Derived: trailing 12 months at year end)−$5.4M−$5.2M−$3.4M
EBITDA−$3.8M (source: Derived: trailing 12 months at year end)−$5.2M−$6.9M−$3.7M
EBIT−$3.8M (source: Derived: trailing 12 months at year end)−$5.2M−$6.9M−$3.8M
Interest expense$14.7K (source: Derived: trailing 12 months at year end)$7.3K$7.6K$9.7K
Pretax income−$3.8M (source: Derived: trailing 12 months at year end)−$5.2M−$6.9M−$3.8M
Tax$0 (source: Derived: trailing 12 months at year end)$0$0$0
NPAT−$3.7M (source: ASX (Markit))−$5.2M−$6.9M−$3.8M
Net interest income$170.7K (source: Derived: trailing 12 months at year end)$128.6K$320.2K$106.7K
EPS basic−$0.013 (source: Derived: trailing 12 months at year end)−$0.023−$0.030−$0.017
EPS diluted−$0.013 (source: Derived: trailing 12 months at year end)−$0.023−$0.030 (source: Derived: trailing 12 months at year end)−$0.017
Sharesn/a234.0M228.0M227.8M
  • ASX (Markit)
  • Derived: trailing 12 months at year end

Financial reports

The company's own filings, newest first